Phathom Pharmaceuticals PHAT 深 滬
交易中 11-04 09:51:41 美东时间
13.35
-0.380
-2.77%
華盛通- 最 高13.635
- 今 開13.61
- 成交量 3.15万股
- 最 低 13.33
- 昨 收 13.73
- 總市值 9.47亿
- 52周最高 16.08
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 2.21
- 委 比 87.10%
- 總股本 7094.37万
- 歷史最高 64.54
- 量 比 1.49
- 振 幅 2.22%
- 歷史最低 2.21
- 每 手 1
- 風險率 3.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phathom Pharmaceuticals Doses First Patient In Phase 2 pHalcon-EoE-201 Clinical Study Evaluating VOQUEZNA Tablets To Treat Eosinophilic Esophagitis
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in
今天 21:03
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals' management team will participate in five upcoming investor conferences between November and December 2025. These events include the Guggenheim Securities Healthcare Innovation Conference in Boston, the Stifel Healthcare Conference in New York, the Jefferies Global Healthcare Conference in London, the Craig-Hallum Alpha Select Conference in New York, and the Evercore Healthcare Conference in Miami. Management will engage i...
11-03 12:59
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
Phathom Pharmaceuticals Raises FY2025 Sales Guidance from $165.000M-$175.000M to $170.000M-$175.000M vs $169.904M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) raises FY2025 sales outlook from $165.000 million-$175.000 million to $170.000 million-$175.000 million vs $169.904 million estimate.
10-30 19:24
Phathom Pharmaceuticals Q3 Adj. EPS $(0.15), Sales $49.504M Beat $46.993M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.55) by 72.48 percent. This is a 85.71 percent increase over losses of $(1.05) per
10-30 19:21
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Phathom Pharmaceuticals announced positive results from additional analyses of its Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) for Non-Erosive Reflux Disease (NERD), published in the American Journal of Gastroenterology. The study showed significant and sustained relief of nighttime GERD symptoms, with patients experiencing meaningful increases in heartburn-free nights starting after the first dose and maintained through 24 w...
10-25 13:59
Phathom Pharmaceuticals To Highlight Gastrointestinal Treatments Through Multiple Engagements Including A Product Theater Presentation On Voquezna Tablets For Gerd At American College Of Gastroenterology 2025 Annual Scientific Meeting In Phoenix, Arizona.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American
10-23 20:14
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
Phathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting in Phoenix, showcasing its leadership in GI treatments, particularly with VOQUEZNA® (vonoprazan) for GERD. Activities include a product theater presentation, exhibit booth presence, and support for a Medscape program. VOQUEZNA is approved for treating and maintaining healing in Erosive GERD, and relieving heartburn in Non-Erosive ...
10-23 12:00
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial And Business Officer
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence Appointment strengthens Phathom's
10-06 20:11
